The agency revived an old treatment for cancer patients, unilaterally approving it for a subset of people with autism. Experts worry that the narrower scope will get lost in the hype.
F.D.A.’s Approval of Drug for Autism Upends Review Process
Written by
in
Disabilities, Doctors, Folic Acid, Food and Drug Administration, Generic Brands and Products, GlaxoSmithKline PLC, Intellectual Disabilities, Kennedy, Robert F Jr, Kenvue Inc, Labeling and Labels (Product), Makary, Marty, Regulation and Deregulation of Industry, Trump, Donald J, United States Politics and Government